Ashby, Donovan M.
Floresco, Stan B. http://orcid.org/0000-0002-5633-243X
Phillips, Anthony G.
McGirr, Alexander http://orcid.org/0000-0002-8425-3958
Seamans, Jeremy K.
Wang, Yu Tian http://orcid.org/0000-0001-8592-0698
Article History
Received: 16 February 2020
Accepted: 25 November 2020
First Online: 4 January 2021
Competing interests
: Y.T.W. and A.G.P. declare a patent related to glutamate receptor function (A Peptide that Specifically Blocks Regulated AMPA Receptor Endocytosis and Hippocampal CA1 Long-term Depression; European 04789721.0, and United States 13/066,700). A.G.P. also holds a US patent entitled “Tetrahydroprotoberbine Compounds and Uses Thereof” in the Treatment of Neurological, Psychiatric and Neurodegenerative Diseases. United States. US20150306092. A.G.P. is a shareholder in Resilience Biosciences Inc., Canada, focused on tetrahydroprotoberberine drug development. D.M.A., S.B.F., A.M., and J.K.S. declare no competing interests.